Melengestrol Acetate Pharmaceutical Ingredient CAS 2919-66-6 Antineoplastic Agent

Melengestrol Acetate Pharmaceutical Ingredient Antineoplastic Agent CAS 2919 66 6
 
Melengestrol Acetate
Cas: 2919-66-6
Molecular formula: C25H32O4
Packing: 5KG/TIN,2TIN/CTN
Unit: KG
Quality Standards: USP31
 
 
Description:
 
Melengestrol (INN, BAN) is a steroidal progestin and antineoplastic agent which was never marketed.An acylated derivative, melengestrol acetate, is used as a growth promoter in animals
Progestogens are synthetic forms of the naturally occurring hormone, progesterone. Progesterone is produced by the corpus luteum . By negative feedback, it reduces pituitary function, thus preventing a female from coming into heat. When administered in conjunction with a luteolytic agent, such as PGF2a or estradiol valerate, progestogens can provide an effective means of resetting the cow's physiological clock. If the progestogen is administered for several days, an artificial corpus luteum can in effect be installed, which can be removed at the producer's discretion.
 
Specifications :
 
Analysis Report
 

 

Application:
Melengestrol acetat is widely used as a growth promoting feed additive in cattle breeding in the USA and several other non-European countries. To explore the physiological effects of MGA four heifers were fed during 8 weeks with 0.5 mg MGA daily as registered in the USA and two heifers each received 0, 1.5 or 5 mg/day, respectively. Plasma samples were collected twice a week and concentrations of MGA, progesterone and estradiol-17beta were quantified. The pulsatile secretion of luteinizing hormone was investigated in 6-hour profiles before and during treatment. After slaughter the reproductive organs were examined and oestrogen residues in edible tissues were measured.
Four days after the beginning of MGA feeding MGA concentrations in plasma reached levels of 30 and 100-400 pg/mL depending on the dose received. Three weeks after the beginning of MGA feeding P4 plasma concentrations had dropped to base levels below 0.3 ng/mL in all three treatment groups. Mean plasma E2-17beta levels increased in physiological range from 1 to 5 pg/mL during 0.5 mg MGA/day feeding with many acyclic peaks. Overdosed MGA decreased E2 levels and suppressed cyclic peaks. Number and size of ovarian follicles were not altered by any treatment. Mean LH levels and pulse frequencies increased significantly during labelled treatment , while higher doses had reducing effects. The development of corpus luteum was suppressed. E2-17beta residues in fat increased about 300% following labelled MGA treatment.

 
Competitive Advantage: